Android app Apple app link

H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

By Yahoo! Finance   |   1 month ago
H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

Stoke Therapeutics (NASDAQ:STOK) is a promising growth stock with a Buy rating and $35 price target by H.C. Wainwright.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.